Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00810719 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
A Phase 2 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00810719 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 30 participants.
The verdict
NCT00810719, a Phase 2 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with erlotinib works in treating patients with metastatic or recurrent pancreatic cancer.
Interventions
- DRUG gemcitabine
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00810719
The ClinicalTrials.gov registry entry for NCT00810719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT00810719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00810719 about?
NCT00810719 is a clinical study titled "Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine...
What is the current status of trial NCT00810719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-04. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00810719?
The interventions under investigation include: gemcitabine (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00810719?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.